NCT06343077 2024-04-02
Intratumoral and Systemic HiltonolĀ® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
Clinical Trials
11 trialsNCT01188096 2023-06-12
Poly-ICLC
Wake Forest University Health Sciences
Phase 2 Completed
NCT02334735 2022-09-15
A Comparison of Matured Dendritic Cells and MontanideĀ® in Study Subjects With High Risk of Melanoma Recurrence
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT01245673 2020-04-06
Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
University of Pennsylvania
Phase 2 Completed
NCT02754362 2020-01-13
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NYU Langone Health
Phase 2 Withdrawn
NCT01437605 2019-12-20
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00262730 2019-06-12
Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00058123 2018-08-21
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00052715 2018-07-18
Poly-ICLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT01984892 2018-01-23
Hiltonol
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT01734564 2017-04-11
Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Completed